Organicell Regenerative Medicine is a leading biotech company based in Miami Beach, FL, specializing in the development of innovative biologic therapies and nano-technologies for a wide range of medical conditions. Their groundbreaking research in nanotechnology has led to the creation of a novel biologic candidate, Zofin, which has received FDA approval for clinical trials in the treatment of knee osteoarthritis, chronic obstructive pulmonary disease (COPD), and COVID-19.
With a mission to pioneer the frontiers of medical science, Organicell is committed to rigorous research, groundbreaking innovation, and the development of regenerative biologic therapies. Their unique approach involves creating ultra-high concentration biologics containing hundreds of billions of extracellular vesicles nanoparticles per ml, which have shown tremendous therapeutic potential in reducing inflammation and promoting tissue regeneration. Through ongoing clinical trials and FDA-approved investigational new drug applications, Organicell aims to develop FDA-approved treatments that can provide consistent patient outcomes.
Generated from the website